California's public health regulator has approved the Irish cleantech firm's non-thermal GENERATIONS system for biohazardous and sharps waste treatment.

Envetec has named Patrick S. Jones, president of Thermo Fisher's Clinical Diagnostics Division, as an independent director to support its US expansion.

Kala Bio will be the sole US distributor of Virotek's ophthalmology genomic testing programme under a one-year deal effective 4 September 2026.

BioStem Technologies has secured GPO contract coverage for VENDAJE and VENDAJE AC through Vizient and Premier, opening hospital access for the first time.

The Chinese battery maker says Model 32140 shipments doubled year-on-year as it targets India's fast-growing light electric vehicle market.

The NASDAQ-listed healthcare group reported 29.7% revenue growth in H1 2026 and repaid an $8m convertible note twelve months ahead of schedule.

The Pennsylvania-based medtech said the CE Mark opens European commercial sales of its intraoperative 3-in-1 imaging platform, which integrates with its ExcelsiusGPS

The CRISPR biotech drew an initial $75m at closing, with further tranches tied to milestones for its HAE gene-editing candidate lonvo-z.

New modelling data links antibiotic disc exposure to clinical benefit, strengthening the rationale for PP353 as a targeted, non-opioid therapy for vertebrogenic lumbar

The Lp(a)HORIZON outcomes trial in 8,323 patients met its Lp(a)-lowering goal but did not reduce the composite cardiovascular endpoint versus

The Paris-based robotics firm said blue-chip automotive, logistics and healthcare operators are among early adopters of its Calvin-40 humanoid robot.

The HORIZON Phase 3 trial of pelacarsen failed its primary cardiovascular endpoint, but royalty backer Royalty Pharma says it still expects a modest positive return.